Kelsey Kern has been with CSL Behring since 2017 where she has managed global, end-to-end clinical trial supply in the Cardiovascular, Hereditary Angioedema (HAE), and Transplant therapeutic areas.
Kelsey Kern
Kelsey Kern has been with CSL Behring since 2017 where she has managed global, end-to-end clinical trial supply in the Cardiovascular, Hereditary Angioedema (HAE), and Transplant therapeutic areas.